Literature DB >> 10772385

Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists.

U Lippert1, A Möller, P Welker, M Artuc, B M Henz.   

Abstract

H1-type antihistamines have recently been reported to inhibit cytokine secretion from human and murine mast cells and basophils. In order to confirm and expand these studies, we have compared several H1-blockers and the H2-blocker ranitidine for their effect on TNF-alpha, IL-3, 6, 8 and GM-CSF release from human leukemic mast (HMC-1) and basophilic (KU812) cells, compared to dexamethasone. Cells were stimulated for 24 h with phorbol myristate acetate (25 ng/ml) and calcium ionophore A 23187 (2.5x10(-7) M) alone or with the drugs added at 10(-4) to 10(-15) M, and production of cytokines was measured by ELISA. All antihistamines caused a dose-dependent inhibition of TNF-alpha release from HMC-1 cells, with maximal effects at 10(-12) M for azelastine, 10(-9) M for loratadine and cetirizine, and 10(-8) M for ranitidine. The inhibitory potency of H1-blockers on cytokines from HMC-1 cells was TNF-alpha >IL-8> or =IL-6> or =IL-3, with no significant effects on GM-CSF. In KU812 cells which failed to secrete TNF-alpha and GM-CSF, the sequence was IL-6 >IL-8 after preincubation. Dexamethasone inhibited all cytokines, but ranitidine only TNF-alpha and IL-3. Antihistamines had no effect on calcium flux in resting or stimulated cells. At the mRNA level, inhibition was only seen with KU812 cells and IL-8 in the presence of azelastine at 10-(10) M. These data show thus distinct inhibitory patterns for different antihistamines during cytokine production from human mast cells and basophils which may contribute to the anti-inflammatory effects of these drugs during treatment of allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772385     DOI: 10.1034/j.1600-0625.2000.009002118.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  25 in total

Review 1.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy.

Authors:  Viktoria Ferencz; Szilvia Meszaros; Emoke Csupor; Edit Toth; Katalin Bors; Andras Falus; Csaba Horvath
Journal:  Osteoporos Int       Date:  2006-01-24       Impact factor: 4.507

Review 3.  [Update on the cutaneous neurobiology of pruritus].

Authors:  U Raap; E Papakonstantinou; M Metz; U Lippert; M Schmelz
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

Review 4.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Allergic rhinitis in children : diagnosis and management strategies.

Authors:  William E Berger
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

6.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.

Authors:  Eustachio Nettis; Maddalena D'Erasmo; Elisabetta Di Leo; Gianfranco Calogiuri; Vincenzo Montinaro; Antonio Ferrannini; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2010-09-22       Impact factor: 4.711

Review 8.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Desloratadine: an update of its efficacy in the management of allergic disorders.

Authors:  David Murdoch; Karen L Goa; Susan J Keam
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Flux change in basophil membrane is not the main pathogenesis for hypersensitivity.

Authors:  Viroj Wiwanitkit
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.